Artiflex versus STAAR[registered] implantable contact lenses for correction of high myopia

To compare two phakic intraocular lenses, Artiflex and STAAR[registered] implantable contact lens [ICL], in high myopia. Isfahan Ophthalmology Clinic, Iran. In a randomized, prospective clinical trial study, 40 eyes of 20 patients who came to Isfahan ophthalmology clinic to correct their refractive error were examined. Artiflex was inserted in 20 eyes and ICL in the other 20 eyes. After 1 year, uncorrected visual acuity [UCVA], best corrected visual acuity [BCVA], contrast sensitivity, intraocular pressure [IOP], and specular microscopy of corneal endothelium were assessed in both the groups. In this study, there was no statistical difference between UCVA, BCVA, IOP, cataract incidence, contrast sensitivity, and specular microscopy, 1 year after surgery. 40% of eyes in the Artiflex group developed anterior chamber cell and flare reaction 1 year postoperatively, but no patient in the ICL group developed the same. So, there is obvious difference in the rate of anterior chamber cell and flare reaction between these two groups. These two lenses have similar outcomes except in the incidence rate of anterior chamber cell and flare reaction that is greater in the Artiflex group. So, these two lenses are safe with predictable outcome in treating high myopia

Outcomes of photorefractive keratectomy with intraoperative mitomycin-C

To report the efficacy, safety, predictability and complications of photo-refractive keratectomy [PRK] with intraoperative application of mitomycin-C [MMC]. This historical cohort study was performed on 1,250 eyes of 625 patients who underwent PRK using the Technolas 217 excimer laser machine by a single surgeon with intraoperative use of MMC 0.02% up to 2 minutes, depending on depth of ablation. A complete ophthalmologic examination was performed which included refraction, uncorrected visual acuity [UCVA], best-corrected visual acuity [BCVA] and slitlamp biomicroscopy. Outcomes were analyzed after one year of follow-up. The mean preoperative spherical equivalent refractive error was -4.85 +/- 2.27 [range, -2.50 to -13.5] diopters [D]. Mean depth of ablation was 89 +/- 22 microns and mean time to reepithelialization was 4.5 +/- 1.7 days. At final follow-up, UCVA of 20/20 and 20/40 or more was achieved in 92.1% and 99.2% of eyes, respectively. One year post-operatively, 69.4% and 91% of eyes were within +/- 0.50 D and +/- 1.00 D of emmetropia. Overall, 62 eyes [4.9%] developed one or two lines of decrease in BCVA, and 50 eyes [4%] developed corneal haze which was grade 1 or 2 in most cases; grade 3 and 4 corneal haze was found in 4 and 2 eyes, respectively. No other adverse event was noted during the study period. PRK with intraoperative application of MMC provides excellent visual outcomes with acceptable safety and predictability, and entails minimal side effects